Peer-influenced content. Sources you trust. No registration required. This is HCN.
Clinical Advances in Hematology & Oncology
Lisocabtagene maraleucel offers a new treatment option for patients with CLL who have progressed on both BTK and BCL2 inhibitors, addressing an important unmet need in this patient population.
Hematology/Oncology August 26th 2024
Medical Professionals Reference (MPR)
Neffy®, an FDA-approved intranasal epinephrine spray, demonstrates bioequivalence to injectable epinephrine for anaphylaxis treatment in patients weighing ≥30kg, potentially reducing barriers to rapid intervention.
Allergy & Immunology August 16th 2024
Practical Neurology
Zunveyl, a prodrug of galantamine, has been formulated to minimize gastrointestinal absorption, potentially addressing common tolerability issues associated with acetylcholinesterase inhibitors in Alzheimer’s treatment.
Neurology August 13th 2024
Oncology News Central (ONC)
Afamitresgene autoleucel offers a novel approach to treating metastatic synovial sarcoma, with an overall response rate of 43.2% in clinical trials, providing a much-needed alternative to traditional chemotherapy.
Oncology, Medical August 12th 2024
The Dermatologist
Roflumilast cream 0.15% demonstrates rapid and significant improvement in itch within 24 hours of the first application, addressing a primary concern for atopic dermatitis patients.
Allergy & Immunology August 8th 2024
Kisunla’s approval introduces a novel treatment option for early Alzheimer’s disease, potentially altering the landscape of AD management with its ability to significantly reduce amyloid plaque levels and slow cognitive decline.
Neurology July 17th 2024